BOTOX® Treatment for Adults With a Wide Lower Face Due to Masseter Muscle Prominence

Masseter Muscle Prominence Clinical Trial

Official title:
BOTOX® (onabotulinumtoxinA) Treatment of Masseter Muscle Prominence: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study

Status Completed

Clinical Trial Summary

This study is designed to evaluate the safety and effectiveness of administering BOTOX for the treatment of Masseter Muscle Prominence (MMP) in adults.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Masseter Muscle Prominence

Clinical Trial Details

NCT number	NCT04073303
Study type	Interventional
Source	Allergan
Contact
Status	Completed
Phase	Phase 3
Start date	August 29, 2019
Completion date	November 10, 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06068855` - A Study to Assess the Effectiveness of BOTOX (Botulinum Toxin Type A) Injections for the Change of Masseter Muscle Prominence in Adult Participants	Phase 3
Recruiting	`NCT06137287` - A Study to Assess Adverse Events and Change of Masseter Muscle Prominence Using BOTOX Injections in Adult Participants	Phase 3
Completed	`NCT03861936` - BOTOX® (onabotulinumtoxinA) Treatment of Masseter Muscle Prominence	Phase 2
Recruiting	`NCT06399718` - A Study to Assess BOTOX Injections for the Change of Masseter Muscle Prominence in Adult Participants	Phase 3
Recruiting	`NCT06387394` - A Study to Assess BOTOX Injections in Adult Participants for the Change of Masseter Muscle Prominence	Phase 3